PharVision Advisers’s Clarivate CLVT Stock Holding History

PharVision Advisers’s Portfolio CLVT Stock Details CLVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-11,683	Closed	-$44.7K	–	733
2025 Q3	$44.7K	Buy	+11,683	New	+$49.1K	0.03%	651

Other funds holding CLVT

LGP

Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return

ENV

Exor N.V. Amsterdam, Netherlands $5.46B AUM 6.21% 1-Year Est. Return

CCP

Clarkston Capital Partners Rochester, Michigan $1.18B AUM 0.37% 1-Year Est. Return

Impactive Capital New York City, New York $1.4B AUM 13.97% 1-Year Est. Return

PGH

Partners Group Holding Baar-Zug, Switzerland $1.47B AUM 8.59% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Atairos Group Bryn Mawr, Pennsylvania $1.76B AUM 16.47% 1-Year Est. Return

PharVision Advisers's CLVT Position: Q4 2025 in Review

PharVision Advisers sold out of Clarivate (CLVT) in Q4 2025, closing a stake of 11,683 shares — an estimated $44.7K sold.

PharVision Advisers first reported a position in CLVT in Q3 2025 and held it in 1 quarter. The position peaked at $44.7K in Q3 2025. 218 funds tracked by Wall St. Rank hold CLVT as of Q4 2025.

PharVision Advisers reported no remaining Clarivate position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 11,683 Clarivate shares in Q4 2025, an estimated $44.7K.
PharVision Advisers first reported a position in Clarivate in Q3 2025 and held it in 1 quarter.
PharVision Advisers's Clarivate position peaked at $44.7K in Q3 2025.
218 funds tracked by Wall St. Rank held Clarivate as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.